The roles of purinergic signaling in psychiatric disorders.
Toruń, Poland. In Acta Biochim Pol, Nov 2015
It is believed that any action leading to the effective increase of adenosine concentration: activation of nucleotide metabolizing ecto-enzymes (mainly NTPDases - nucleoside triphosphate diphosphohydrolases), inhibition of adenosine deaminase and/or adenosine kinase activity as well as therapies using P1 receptor agonists (adenosine or its analogues) might be beneficial in therapy of psychiatric disorders.
Adenosine receptor targets for pain.
Halifax, Canada. In Neuroscience, Nov 2015
Endogenous adenosine levels can be augmented by inhibition of metabolism (via adenosine kinase) or increased generation (via nucleotidases), and these approaches have implications for pain.
Comorbidities in Neurology: Is adenosine the common link?
Portland, United States. In Neuropharmacology, Oct 2015
Here we will specifically focus on the 'adenosine hypothesis of comorbidities' implying that astrocyte activation, via overexpression of adenosine kinase (ADK), induces a deficiency in the homeostatic tone of adenosine.
The adenosine neuromodulation system in schizophrenia.
Coimbra, Portugal. In Int Rev Neurobiol, 2013
This proposal should also provide a rationale to assist the design of future therapeutic intervention targeting the adenosine modulation system to manage schizophrenia endophenotypes: these should not be based only on an attempt to target adenosine kinase-A1 receptors or only A2A receptors, but should instead simultaneously target these two arms of the adenosine modulation system.